AI-Based Fidelity Feedback to Enhance CBT
Launched by UNIVERSITY OF PENNSYLVANIA · Apr 15, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new technology called LyssnCBT, which aims to improve the quality of Cognitive Behavioral Therapy (CBT) provided to patients by therapists in community mental health settings. Researchers from the University of Pennsylvania and the technology company Lyssn.io, Inc. want to see if using this technology can help therapists provide better therapy compared to the usual methods. The trial will first test the technology in five mental health agencies to understand any challenges in using it before comparing its effectiveness to standard services.
To participate in this study, therapists must work at a community mental health center in Philadelphia, be able to conduct therapy sessions in English, and agree to have their sessions recorded for research purposes. Clients who receive therapy must also speak English and be willing to allow the research team to collect data from their sessions. Participants can expect to be part of a project that aims to enhance the quality of mental health care, helping both therapists and clients improve their therapy experience.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Therapists
- • Able to participate in therapy sessions conducted in English
- • Employed at a Philadelphia CMH treatment center that allows the recruitment and participation of therapists in research-related activities
- • Willing to allow their session recordings to be used for research purposes
- • Computer and internet access
- • Supervisors
- • Oversee participating therapists
- • Computer and internet access
- • Clients
- • Able to participate in therapy sessions conducted in English
- • Willing to allow the team to collect data and use their session recordings for research purposes
- Exclusion Criteria:
- • Unwilling to allow the research team to access their therapy session recordings
About University Of Pennsylvania
The University of Pennsylvania, a prestigious Ivy League institution located in Philadelphia, is renowned for its commitment to advancing medical research and improving healthcare outcomes. As a clinical trial sponsor, the university leverages its extensive resources, interdisciplinary expertise, and cutting-edge facilities to conduct innovative studies across various therapeutic areas. With a focus on translating scientific discoveries into clinical applications, the University of Pennsylvania fosters collaborations among leading researchers, clinicians, and industry partners, ensuring rigorous trial design and adherence to ethical standards. Through its dedication to excellence in research and education, the university plays a pivotal role in shaping the future of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
Torrey A Creed, PhD
Principal Investigator
Director, The Penn Collaborative for CBT and Implementation Science
David Atkins, PhD
Principal Investigator
CEO, Lyssn
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials